2026年3月16日,Theravance Biopharma的高级副总裁以每股13.96美元出售了超过31000个股票. On March 16, 2026, Theravance Biopharma’s senior vice president sold over 31,000 shares for $13.96 each.

2026年3月16日,Theravance Biopharma的高级副总裁Rhonda Farnum以每股13.96美元的价格出售了31 067个股票,使她的股份减少11.78%至232 699股,估值约为3250万美元. On March 16, 2026, Theravance Biopharma’s senior vice president Rhonda Farnum sold 31,067 shares at $13.96 each, reducing her stake by 11.78% to 232,699 shares, valued at about $3.25 million. 交易是在证券交易委员会提交的文件中披露的. The sale was disclosed in an SEC filing. 3月18日,股价收盘时为13.83美元,跌幅0.09美元,交易量低于平均水平. On March 18, the stock closed at $13.83, down $0.09, with trading volume below average. 这家公司开发呼吸系统和罕见疾病的治疗方法, 市值为7亿7700万美元. The company, which develops treatments for respiratory and rare diseases, has a market cap of $700.77 million. 分析师提供混合评级,共识是"中等购买",目标为22.60美元. Analysts offer mixed ratings, with a consensus “Moderate Buy” and a $22.60 target.